{"id":86,"date":"2020-04-22T05:23:11","date_gmt":"2020-04-22T05:23:11","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=86"},"modified":"2020-05-12T05:42:37","modified_gmt":"2020-05-12T05:42:37","slug":"6-april-2020-tocilizumab-repeat-doses-for-management-of-cytokine-storm-in-critically-ill-patients","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/6-april-2020-tocilizumab-repeat-doses-for-management-of-cytokine-storm-in-critically-ill-patients\/","title":{"rendered":"(6 April 2020) Tocilizumab- repeat doses for management of Cytokine storm in critically ill patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\"><strong>Tocilizumab treatment in COVID\u201019: A single center experience<\/strong><\/p>\n<p>https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jmv.25801<\/p>\n<p class=\"\">In the present study, authors discuss the treatment response of Tocilizumab (TCZ) therapy in COVID\u201019 infected patients. The demographic, treatment, laboratory parameters of C\u2010reactive protein (CRP) and IL\u20106 before and after TCZ therapy and clinical outcomes were retrospectively assessed. Totally 15 patients with COVID\u201019 were included in this study. Elevated IL\u20106 is the indication for TCZ use in COVID\u201019. The levels of IL\u20106 before TCZ administration ranged from 16.4 to 627.1\u2009pg\/mL (2 times to nearly 90 times higher than normal). After starting TCZ therapy, serum IL\u20106 level in 10 (66.7%) patients tended to spike shortly in first and then decreased. TCZ appears to be an effective treatment for these critically ill patients with elevated IL\u20106, the repeated dose of the TCZ is recommended.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tocilizumab treatment in COVID\u201019: A single center experience https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jmv.25801 In the present study, authors discuss the treatment response of Tocilizumab (TCZ) therapy in COVID\u201019 infected patients. The demographic, treatment, laboratory parameters of C\u2010reactive protein (CRP) and IL\u20106 before and after&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/6-april-2020-tocilizumab-repeat-doses-for-management-of-cytokine-storm-in-critically-ill-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(6 April 2020) Tocilizumab- repeat doses for management of Cytokine storm in critically ill patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/86"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=86"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/86\/revisions"}],"predecessor-version":[{"id":87,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/86\/revisions\/87"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=86"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=86"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=86"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}